Capital Asset Advisory Services LLC Buys New Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Capital Asset Advisory Services LLC purchased a new position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNAGet Rating) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 43,000 shares of the company’s stock, valued at approximately $357,000.

Several other institutional investors have also modified their holdings of DNA. Viking Global Investors LP purchased a new position in shares of Ginkgo Bioworks during the 3rd quarter valued at about $3,511,109,000. General Atlantic L.P. purchased a new position in Ginkgo Bioworks during the third quarter valued at approximately $1,331,539,000. Senator Investment Group LP bought a new position in shares of Ginkgo Bioworks in the third quarter worth approximately $912,171,000. ARK Investment Management LLC increased its stake in shares of Ginkgo Bioworks by 85.9% in the fourth quarter. ARK Investment Management LLC now owns 43,180,820 shares of the company’s stock worth $358,833,000 after purchasing an additional 19,949,965 shares in the last quarter. Finally, Baillie Gifford & Co. lifted its stake in shares of Ginkgo Bioworks by 20.3% during the 4th quarter. Baillie Gifford & Co. now owns 109,450,171 shares of the company’s stock valued at $909,530,000 after buying an additional 18,447,361 shares in the last quarter.

Shares of DNA stock traded down $0.20 on Monday, reaching $3.64. The company’s stock had a trading volume of 849,160 shares, compared to its average volume of 16,339,695. The stock’s fifty day simple moving average is $3.99 and its 200-day simple moving average is $8.02. Ginkgo Bioworks Holdings, Inc. has a 1 year low of $2.62 and a 1 year high of $15.86. The company has a current ratio of 12.79, a quick ratio of 12.76 and a debt-to-equity ratio of 0.01.

Ginkgo Bioworks (NYSE:DNAGet Rating) last released its quarterly earnings data on Monday, March 28th. The company reported ($0.99) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by ($0.95). Sell-side analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -0.13 earnings per share for the current fiscal year.

Several brokerages have recently commented on DNA. BTIG Research lowered their price objective on Ginkgo Bioworks from $12.00 to $6.00 in a research report on Thursday, March 31st. The Goldman Sachs Group initiated coverage on Ginkgo Bioworks in a research note on Wednesday, February 23rd. They issued a “neutral” rating and a $7.00 price target for the company. Zacks Investment Research cut shares of Ginkgo Bioworks from a “buy” rating to a “hold” rating in a research report on Monday, April 4th. Cowen initiated coverage on shares of Ginkgo Bioworks in a research report on Wednesday, March 2nd. They set an “outperform” rating and a $12.00 target price for the company. Finally, Bank of America reiterated a “neutral” rating and issued a $6.00 price target on shares of Ginkgo Bioworks in a report on Tuesday, February 1st. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $8.82.

Ginkgo Bioworks Company Profile (Get Rating)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Featured Stories

Want to see what other hedge funds are holding DNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ginkgo Bioworks Holdings, Inc. (NYSE:DNAGet Rating).

Institutional Ownership by Quarter for Ginkgo Bioworks (NYSE:DNA)

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.